Tag: Regulatory

FORM 8.5 (EPT/RI)

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

VANCOUVER, British Columbia, July 21, 2025 (GLOBE NEWSWIRE) -- ERAG Energie & Rohstoff AG PCC (the “Acquiror), a private investment a private investment holding company incorporated in Liechtenstein, announces that on July 17, 2025, the Acquiror, along with two joint actors HMS Bergbau AG (“HMS”) and LaVo Verwaltungsgesellschaft MBH (“LaVo”), acquired Common Shares of Belmont Resources Inc. (TSX-V: BEA) (the “Issuer”). The Issuer completed a private placement of Common Shares, issuing a total of 26,300,00 shares at a price of $0.045 per share for proceeds of $1,183,500 (the “Private Placement”). Under the Private Placement, the Acquiror purchased 4,000,000 Common Shares, HMS purchased 15,000,000 Common Shares and LaVo purchased 7,300,000 Common Shares.